Stay updated with breaking news from Nasdaq Rxrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the sale, the director now directly owns 7,229,861 shares in the […]
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 6.1% during trading on Monday following insider selling activity. The stock traded as low as $10.50 and last traded at $10.51. Approximately 3,359,534 shares changed hands during trading, a decline of 54% from the average daily volume of 7,262,308 shares. The stock had previously […]
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 6.1% during trading on Monday after an insider sold shares in the company. The company traded as low as $10.50 and last traded at $10.51. Approximately 3,359,534 shares traded hands during trading, a decline of 54% from the average daily volume of 7,262,308 shares. […]
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]